35 results
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
Applicable NYSE American rules require a majority of a listed company’s board of directors to be comprised of independent directors within one year of listing … a majority of the number of votes necessary to take such action. Mr. Kopfli was then terminated from his position as Vice Chairman and Chief Strategy
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
Applicable NYSE American rules require a majority of a listed company’s board of directors to be comprised of independent directors within one year of listing … a majority of the number of votes necessary to take such action. Mr. Kopfli was then terminated from his position as Vice Chairman and Chief Strategy
10-K
2023 FY
EX-3.3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
and the holders of at least a majority of the then outstanding Shares (the “Required Holders”), and any such written amendment, modification or waiver
10-K
2023 FY
EX-4.2
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
to one vote, including in all elections of directors. The vote of the holders of a majority of the issued and outstanding shares of Common Stock … be removed by the stockholders with or without cause upon the vote of a majority of the holders of Common Stock then entitled to vote. Except as otherwise
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
American rules require a majority of a listed company’s board of directors to be comprised of independent directors within one year of listing … forth in the employment agreement.
On November 27, 2023, Mr. Kopfli was removed from our board of directors by our stockholders having a majority
S-8
xjuh7lic3ijl
12 Apr 24
Registration of securities for employees
7:22pm
8-K
wnuxh 6h4mge0
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-3.2
nezfgf c4
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-3.1
zoy31cesshv936m1 u8l
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
838wyy29336
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
tgxsgkeu66mt
20 Feb 24
Prospectus supplement with pricing info
5:28pm